

## References

I-32

1. Przeklasa-Muszynska A, Kocot-Kepska M, Dobrogowski J, et al. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. *Pharmacological Reports*. 2016;68(5):1069-1075.
2. Hutson P, Backonja M, Knurr H. Intravenous Lidocaine for Neuropathic Pain: A Retrospective Analysis of Tolerability and Efficacy. *Pain Medicine*. 2015; 68(5):531-536.
3. Van der Wal SEI, van den Heuvel SAS, Radema SA, et al. The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain. *Eur J Pain*. 2016;20(5):655-674.
4. Hayes, Inc. Hayes Medical Technology Directory Report. *Intravenous Lidocaine Infusion for Neuropathic Pain: A Review of Reviews*. Lansdale, PA: Hayes, Inc.; Apr, 2017.
5. Hayes, Inc. Hayes Health Technology Brief. *Intravenous Ketamine for Chronic Nonmalignant Pain*. Lansdale, PA: Hayes, Inc.; 03/18/2021
6. Vadivelu N, Schermer E, Kodumudi V, et al. Role of ketamine for analgesia in adults and children. *Journal of Anaesthesiology Clinical Pharmacology*. 2016;32(3):298-306.
7. Micromedex DrugDex Compendium®. 2024. Lidocaine Hydrochloride.
8. Micromedex DrugDex Compendium®. 2024. Ketamine Hydrochloride.
9. Kim YC, Castaneda AM, Lee CS, et al. Efficacy and safety of lidocaine infusion treatment for neuropathic pain: a randomized, doubleblind, and placebo-controlled study. *Reg Anesth Pain Med*. May 2018;43(4):415-424. PMID 29381569
10. Przeklasa-Muszynska A, Kocot-Kepska M, Dobrogowski J, et al. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. *Pharmacol Rep*. 2016;68(5):1069-1075.
11. Motov S, Mai M, Pushkar I, et al. A prospective randomized, double-dummy trial comparing IV push low dose ketamine to short infusion of low dose ketamine for treatment of pain in the ED. *Am J Emerg Med*. 2017;35(8):1095-1100.
12. Hayes, Inc. Hayes Medical Technology Directory Report. *Ketamine as Primary Therapy for Treatment-Resistant Unipolar Depression or Posttraumatic Stress Disorder*. Lansdale, PA: Hayes, Inc.; 11/21/2017. Accessed on 2/20/2023
13. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Lidocaine.
14. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Ketamine.
15. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
16. Voineskos D, Daskalakis ZJ, Blumberger DM, et al. Management of treatment-resistant depression: challenges and strategies. *Neuropsychiatric Disease and Treatment*. 2020; 16:221-234.

17. Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression. *Molecular Psychiatry*. 2020; 25:1592-1603.
18. Bahji A, Vazquez GH, Zarate CA, et al. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. *J Affect Disord*. 2021; 278:542-555.
19. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. *Am J Psychiatry*, 2021; 178(5):383-399.
20. Ketamine In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 31, 2023.
21. Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for non-psychotic treatment-resistant major depression. *NEJM*, 2023; 388(25):2315-2325.